Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 19/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.57 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191703 | 0.87 | PDE10A (1.00) | PDE10APDE4APDE4BPDE3BPDE3A | |
| SCHEMBL4185917 | 0.86 | PDE10A (1.00) | PDE10APDE4APDE4BPDE3BPDE3A | |
| SCHEMBL5480778 | 0.79 | PDE10A (1.00) | PDE10A | |
| SCHEMBL4778718 | 0.77 | PDE10A (0.71) | PDE10A | |
| SCHEMBL8074299 | 0.77 | PDE10A (0.81) | PDE10APDE4APDE4BPDE3BPDE3A | |
| SCHEMBL13909580 | 0.76 | PDE10A (0.81) | PDE10APDE4APDE4BPDE3BPDE3A | |
| SCHEMBL4776324 | 0.75 | PDE10A (0.67) | PDE10A | |
| SCHEMBL8074171 | 0.74 | PDE10A (0.59) | PDE10A | |
| SCHEMBL8081499 | 0.74 | PDE10A (0.59) | PDE10A | |
| SCHEMBL8080143 | 0.74 | PDE10A (0.59) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062277-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062277-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062277-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. | 2009-03-05 | — | — | US | disclosed |
| WO-2009025823-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009025823-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062277-A1 | PHOSPHODIESTERASE 10 INHIBITORS | PDE5A, PDE12, PDE10A | PDE10A 3/4885PDE4A 4/4885PDE4B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.